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Summary:  
Overview: 
 My name is Cellas Ari’ka Hayes, and I am a first-year graduate student in the School of 
Pharmacy Department of BioMolecular Sciences. I am pursuing a Ph.D. in Pharmaceutical 
Sciences with an emphasis in Pharmacology. My project will assess the effects of insulin-like 
growth factor-1 (IGF-1), an anabolic polypeptide on the damage caused by ischemic stroke 
including glial cell death, neuronal tress, infarct size, neurological deficits, and behavioral changes. 
Intellectual Merit: 
Ischemia is one of the largest causes of neurological deficits that in elderly individuals in 
the United States[1]. Since our life expectancy has increased concurrently with our predispositions 
to stroke, it is necessary to find ways to treat acute ischemia. On the forefront, discovering how 
ischemia affects the brain at the cellular level is critical to discover pharmacological treatments for 
stroke. Clinical studies have shown lower IGF-1 serum levels are more common in individuals 
who have increased damage caused by ischemia. There is also an increase in unfavorable outcomes 
with reduced IGF-1 using the Modified Rankin Scale (MRS) [2]. Other studies have shown an 
inverse relationship between IGF-1 levels and survival rate of individuals who experienced a 
stroke [3, 4]. In vivo studies have also shown that administering IGF-1 pre or post stroke attenuates 
damage caused by ischemia [5-8]. In this project, I will try to elucidate IGF-1’s role in stroke.  
The most difficult task for this project will be learning to perform middle cerebral artery 
occlusion (MCAO) to induce ischemia on transgenic mice where IGF-1 has been removed in either 
neurons or astrocytes. To understands the effects of ischemia and IGF-1’s role, locomotion, 
strength, and behavior will be assessed: avoidance memory, grip strength, cat walk, adhesive tape 
test, cylinder test, pasta test, and rotarod. Neurological deficit score will be assessed immediately 
after reperfusion as described by Jiang et al[8]. After all behavioral test are conducted, the amount 
of tissue death (infarct) will be quantified using the cresyl violet staining protocol adopted from 
Rousselet et al [9]. Other analysis includes quantifying the number of TUNEL positive cells, the 
amount of glutamate release by the target cells, and glial cell changes in the infarct and periinfarct 
zone. Changes in miRNAs (mir33a, 320b,92b,29b,29c,30a, and 15a), caspase3&9, Akt/gsk3b/P70 
s6k cascade, and phosphorylated ERK to ERK pathway will also be quantified to see if removal 
of IGF-1 in neurons and/or astrocytes alters these pathways known to change in ischemia. To 
achieve a power of 0.8 based on type I error of 5% with a 15% group difference, 16 mice will be 
needed to detect a significant difference.   
External Opportunity:  
This proposed research will be submitted to the NIH through the Ruth L. Kirschstein 
National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote 
Diversity in Health-Related Research (Parent F31 -Diversity). My sponsor will be my mentor, Dr. 
Nicole Ashpole who is currently funded for the NIA for a different research question. The potential 
funding includes a stipend of $24,323 limited to 5 years of support and 60% of the actual tuition 
level at the applicant institution, up to $16,000 per year, will be also provided. There are three due 
dates within the year and my plans are to submit Fall 2020. This award is given to students 
classified as minorities, disabled, low-income, or come from disadvantage rural/inner-city 
backgrounds. Receiving this fellowship will give me the foundation needed to apply for the NIH 
(or other outside) funding. This fellowship will allow me to receive national funding which will 
start my journey as a well-known scientist which could lead to other national funding sources.  
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